NCT06878417 Cannabinoids for Osteoarthritis Pain Effectiveness Trial
| NCT ID | NCT06878417 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Osteoarthritis of Knee |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-01-29 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-01-29 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to investigate whether oral cannabis extracts can effectively manage pain caused by osteoarthritis (OA), a common joint condition affecting one in seven Canadians. Current OA treatments often have limited effectiveness and may cause side effects. As a result, many individuals with OA turn to medical cannabis for pain relief, despite limited scientific evidence supporting its efficacy. The goal of this study is to assess the feasibility of a larger trial evaluating the effects of two cannabis compounds-CBD and THC-compared to a placebo (a look-alike substance containing no active drug) on pain interference in patients with hip and/or knee osteoarthritis. Participants will: * Take either CBD, THC, or a placebo capsule daily for 8 weeks * Complete follow-ups remotely, with no in-person clinic visits required * Maintain a diary tracking their study drug usage and any additional pain medications
Eligibility Criteria
Inclusion Criteria: 1. Age 40-80 years 2. Diagnosed with hip and/or knee osteoarthritis as per the American College of Rheumatology criteria 3. Experiencing moderate to severe pain interference as indicated by a PROMIS-PI SF-6a T-score ≥ 60 4. Have not initiated any new analgesics or osteoarthritis treatments in the previous 4 weeks 5. Able to self-report, understand and read English or French Exclusion Criteria: 1. Hip or knee surgery planned in the coming 4 months, 2. Injection into the affected joint(s) within the past 3 months (e.g., cortisone, plasma-rich protein, etc.), 3. Planned injection into the affected joint(s) during trial period, 4. Inflammatory arthritis (e.g., rheumatoid arthritis, Psoriatic arthritis, gout, etc.), 5. Contraindications to taking cannabis/cannabinoids, 6. Used nabilone or nabiximols in the last 30 days, 7. Used cannabis (medical or recreational) in the last 30 days (to allow sufficient washout), 8. A history of diagnosed cannabis use disorder or dependence, 9. Active substance use disorder, 10. Current DSM-V diagnosis of bipolar disorder, major depression, or psychosis, 11. An uncontrolled medical or major psychiatric disorder, 12. Currently on warfarin, 13. Known pregnancy or currently breastfeeding, 14. Men and women planning a pregnancy during the study or in the 12 weeks after stopping IPs 15. No fixed address or a plan to change addresses in the coming 4 months, 16. Known or suspected allergy to palm/coconut oil
Contact & Investigator
Dr. Hance Clarke, MD
PRINCIPAL INVESTIGATOR
University Health Network, Toronto
Frequently Asked Questions
Who can join the NCT06878417 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 80 Years, studying Osteoarthritis of Knee. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06878417 currently recruiting?
Yes, NCT06878417 is actively recruiting participants. Contact the research team at sonalben.thaker@uhn.ca for enrollment information.
Where is the NCT06878417 trial being conducted?
This trial is being conducted at Toronto, Canada, Toronto, Canada, Montreal, Canada.
Who is sponsoring the NCT06878417 clinical trial?
NCT06878417 is sponsored by University Health Network, Toronto. The principal investigator is Dr. Hance Clarke, MD at University Health Network, Toronto. The trial plans to enroll 100 participants.